Prebiotic composition beneficial to body health

Abstract

The invention provides a prebiotic composition beneficial to body health. The prebiotic composition is prepared from fructo-oligosaccharide, L-arabinose, inulin and betaine. The prebiotic composition provided by the invention can relieve constipation and has a remarkable blood glucose reducing effect.

Description

Technical Field

[0001] The present invention provides a prebiotic composition beneficial to health, which not only helps to relieve constipation, but also can regulate blood sugar. The present invention belongs to the field of food. Background Art

[0002] Oligofructose is a non-reducing sugar. It is a functional oligosaccharide such as sucrose trisaccharide, sucrose tetrasaccharide and sucrose pentasaccharide, which is formed by the combination of 1-3 fructoses with the fructoses in sucrose through glycosidic bonds. The degree of polymerization is 2-9. Oligofructose is a natural active ingredient, which is widely found in many plants, such as bananas, garlic, onions, barley, wheat and malt. Oligofructose has been proven to be the only all-natural ingredient with both strong bifidus factors and water-soluble dietary fiber. It is recognized by more than 200 countries and regions worldwide and is widely used in food, health products, alcohol, cosmetics and feed. Oligofructose can proliferate beneficial bacteria and improve immunity. Oligofructose is not absorbed by the human digestive system. After taking it, it will not be broken down into small molecular monosaccharides such as glucose in the body, so it will not cause blood sugar fluctuations and is friendly to diabetics. Oligofructose is not absorbed by the stomach and small intestine. After entering the large intestine, it ferments to produce organic acids, which creates an acidic environment in the intestine, increases calcium solubility, and thus promotes calcium absorption in the body. Oligofructose can also improve lipid metabolism and lower cholesterol.

[0003] L-arabinose is a natural five-carbon aldose that is almost not utilized by the human body. It can combine with sucrase in the small intestine to reduce enzyme activity, reduce the digestion and absorption of sucrose, and thus reduce the increase in blood sugar and insulin levels caused by sucrose. L-arabinose is also a monosaccharide prebiotic. As a nutrient selectively utilized by microorganisms, prebiotics can improve the metabolism of beneficial bacteria, promote the proliferation of beneficial bacteria, regulate the composition, abundance and activity of intestinal flora, and maintain the balance of intestinal microecology. In existing studies, the dosage of L-arabinose is generally high. For example, Chen Zhiheng reported (Effects of L-arabinose on Weight Loss and Hypoglycemic Function in Rats with Metabolic Syndrome, Modern Food. 2022, 28(08), 114-117) that the low-dose group of L-arabinose was 0.03g·kg -1 The combination of L-arabinose's intestinal flora regulation and its defecation-promoting properties due to increased single intake can enhance intestinal regulation and help improve intestinal diseases such as constipation and colitis.

[0004] (Constipatio-relieving effect of L-arabinose[J].Tropical Journal ofPhaarmaceutical Research,2020,19(1),95-99) et al. intervened with L-arabinose at doses of 0.5g / kg BW, 0.75g / kg BW and 2.5g / kg BW for 15 days and found that 0.75g / kg BW L-arabinose had a better effect in relieving constipation in mice with experimental constipation established by compound diphenoxylate.

[0005] Inulin is a carbohydrate that does not cause an increase in glucose in urine. It is not hydrolyzed into monosaccharides in the upper part of the intestine, so it does not increase blood sugar levels and insulin content. However, inulin is easily hydrolyzed into fructose under dilute acid, and is a good raw material for the production of oligofructose, polyfructose, high fructose syrup, crystalline fructose and other products.

[0006] Betaine is an alkaloid that is widely present in animals and plants. It has anti-tumor, anti-hypertensive, anti-peptic ulcer and gastrointestinal dysfunction effects, but there are no relevant research results on constipation and blood sugar. Summary of the invention

[0007] The object of the present invention is to provide a prebiotic composition which is beneficial to human health.

[0008] To achieve the above object, the present invention adopts the following technical solutions:

[0009] A prebiotic composition beneficial to health, comprising:

[0010] (1) 50-98% by weight of oligofructose;

[0011] (2) 0.2-0.7% by weight of L-arabinose;

[0012] (3) 0.2-0.7% by weight of inulin;

[0013] (4) 0.2-0.7% by weight of betaine;

[0014] (5) Appropriate amount of water.

[0015] In the prebiotic composition provided by the present invention, the oligofructose is selected from oligofructose powder or oligofructose syrup, preferably oligofructose syrup, and the concentration of the oligofructose syrup is 40%-98%. Preferably, the concentration of the oligofructose syrup is 50-95%.

[0016] In the prebiotic composition provided by the present invention, the dosage of the oligofructose syrup is in the range of 10-50 g, the dosage of L-arabinose is in the range of 0.01-0.5 g, the dosage of inulin is in the range of 0.01-0.5 g, and the dosage of betaine is in the range of 0.01-0.5 g.

[0017] As a preferred embodiment, in the prebiotic composition provided by the present invention, the amount of the oligofructose syrup is in the range of 20-25 g, the amount of L-arabinose is in the range of 0.1-0.2 g, the amount of inulin is in the range of 0.1-0.2 g, the amount of betaine is in the range of 0.05-0.15 g, and the amount of water is in the range of 0.2-1 g.

[0018] More preferably, the amount of the fructooligosaccharide syrup is in the range of 20-20.5 g, the amount of L-arabinose is in the range of 0.1-0.15 g, the amount of inulin is in the range of 0.1-0.15 g, the amount of betaine is in the range of 0.1-0.15 g, and the amount of water is in the range of 0.2-0.5 g.

[0019] In the present invention, the prebiotic composition can be further prepared into tablets, granules, capsules, oral liquids; or added into food or beverages as nutritional ingredients.

[0020] The present invention provides use of the prebiotic composition in preparing a product for relieving constipation.

[0021] The present invention also provides use of the prebiotic composition in preparing a product for regulating blood sugar.

[0022] The prebiotic composition provided by the present invention can exert a significant synergistic effect in relieving constipation. The effect of oligofructose in relieving constipation is dose-dependent, and the effect of oligofructose at a lower dosage on constipation is very weak. In the present invention, we added a small dose of L-arabinose, inulin and betaine composition to oligofructose, and the composition can make oligofructose exert a significantly stronger effect of relieving constipation at a lower dosage than oligofructose alone. With the increase of the dosage of oligofructose, the effect of oligofructose in relieving constipation is enhanced, and the promotion effect of a small dose of L-arabinose, inulin and betaine composition on oligofructose in relieving constipation is weakened. Therefore, a small dose of L-arabinose, inulin and betaine composition has an unexpected synergistic effect on relieving constipation for a lower dosage of oligofructose.

[0023] The prebiotic composition provided by the present invention can also prolong the hypoglycemic action time of oligofructose, thereby steadily reducing blood sugar levels. In the experiment, we found that although oligofructose can play a hypoglycemic effect, this effect is short-lived and the hypoglycemic effect that can be played is limited. After adding a small dose of L-arabinose, inulin and betaine to oligofructose, the hypoglycemic action time of oligofructose is significantly extended. Since oligofructose syrup not only has a significant hypoglycemic effect, long-term use will not cause hypoglycemia, and also has the effects of weight loss, lowering blood lipids, etc., it is very suitable for diabetic patients, especially gestational diabetes patients and adolescent obese patients. DETAILED DESCRIPTION

[0024] The specific embodiments described herein are only used to explain the present invention and are not used to limit the present invention.

[0025] Example 1: Effect of the prebiotic composition of the present invention on constipated mice

[0026] Experimental animals: SPF grade C57BL / 6 male mice, weighing 23-28g, were raised in an environment with a room temperature of 18-28°C and a relative humidity of 40%-70%, with free access to water. Ordinary feed was adaptively fed for 1 week.

[0027] Dosage grouping and model establishment: The mice were randomly divided into a blank group, a model group and a treatment group, and were gavaged for 4 weeks according to the doses in Table 1 (Aju sweet group: L-arabinose + inulin + betaine, (0.02 + 0.02 + 0.01) g / kg; Composition 1 group: oligofructose + L-arabinose + inulin + betaine, (3 + 0.02 + 0.02 + 0.01) g / kg; Composition 2 group: oligofructose + L-arabinose + inulin + betaine, 5 + 0.02 + 0.02 + 0.01 g / kg), and the blank group and the model group were given an equal amount of normal saline. After 4 weeks, the mice were fasted for 20 hours but not water, and the mice in the model group and the treatment group were gavaged with 50 mg / kg of diphenoxylate, and the blank group was given an equal amount of normal saline. 0.5h later, the mice in the blank group and the model group were gavaged with physiological saline and 0.2ml / mouse ink filtrate, and the mice in the drug administration group were gavaged with the corresponding composition and 0.2ml / mouse ink filtrate.

[0028] Mice were housed in single cages. After intragastric administration, they were allowed to drink water and eat normally. From the time of intragastric administration of ink, the time of the first black stool, the number of black stools excreted within 8 hours, and the weight of black stools excreted within 8 hours were recorded.

[0029] Statistical methods: The experimental data are The t test was used for comparison between the groups. P < 0.05 indicated a significant statistical difference, and P < 0.01 indicated a very significant statistical difference.

[0030] Table 1. Effects of the composition on black stool in constipated mice ( n=9~10)

[0031]

[0032] Note: Compared with the model group, # P<0.05, ## P<0.01; compared with the same dosage of oligofructose group, * P<0.05, ** P<0.01.

[0033] The time of first defecation in the model group was significantly shorter than that in the blank group, and the number of black stool particles and the weight of black stool in 8 hours were significantly greater than those in the blank group, indicating that the constipation model of mice was successfully established.

[0034] The effect of oligofructose group on constipated mice was dose-dependent: compared with the model group, oligofructose group 1 had no significant effect on the first bowel movement, the number of defecation cases within 8 hours, and the fecal weight within 8 hours; the first bowel movement time in oligofructose group 2 was significantly reduced, and the number of defecation cases within 8 hours and the fecal weight within 8 hours were significantly increased, with statistical differences. The dosage of oligofructose in oligofructose group 1 mice was 3g / kg, which is about 20g for humans based on body surface area; the dosage of oligofructose in oligofructose group 2 mice was 5g / kg, which is about 35g for humans based on body surface area.

[0035] The ajutian group had no significant effect on the first defecation time, the number of black stools in 8 hours, and the stool weight in 8 hours in constipated mice, which was related to the low dosage of arabinose and inulin, while betaine had no effect on constipation.

[0036] Compared with the model group, the time of first defecation in the combination group was significantly reduced, and the number of black stool particles in 8 hours and the weight of black stool in 8 hours were significantly increased, with significant or very significant statistical differences. Compared with the oligofructose group 1, the combination group 1 had a significant effect on the time of first defecation, the number of black stool particles in 8 hours and the weight of black stool in 8 hours in constipated mice, with significant or very significant statistical differences; compared with the oligofructose group 2, the combination group 2 had a significant effect on the time of first defecation and the weight of black stool in 8 hours in constipated mice, with significant statistical differences, but there was no significant difference in the number of black stools in 8 hours.

[0037] The above results show that low-dose oligofructose or arabinose inulin and betaine combination has no significant improvement effect on mouse constipation. A small dose of arabinose inulin and betaine combination can significantly improve the constipation effect of low-dose oligofructose, but has no significant improvement effect on constipation improvement of high-dose oligofructose.

[0038] Example 2: Effect of the prebiotic composition of the present invention on blood glucose in rats with impaired glucose tolerance

[0039] Experimental animals: SPF grade Kunming (SD) rats, half male and half female, weighing 250±50g, were raised in an environment with a room temperature of 18-28°C and a relative humidity of 40%-70%, with free access to water. Ordinary feed was adaptively fed for 1 week.

[0040] Feed: High-fat feed consists of 75% basal feed, 10% palm oil, and 15% sucrose.

[0041] Model establishment: SD rats were randomly divided into a blank group and a model group. The rats in the blank group were given a basic diet, and the rats in the model group were given a high-fat diet. After 3 weeks of feeding, the model group was injected with 2% alloxan solution, and the dosage was calculated as 80 mg / kg on the first day, 80 mg / kg on the third day, and 40 mg / kg on the fifth day. One week after alloxan injection, a glucose tolerance test (OGTT) was performed. After fasting for 24 hours, 20% glucose 2g / kg body weight was gavaged, and blood was collected from the tail vein at 0, 30, 60, 90 and 120 minutes, respectively. The blood glucose value at each time point was detected by the glucose oxidase method, and the area under the blood glucose curve (area under the cruve, AUC) was calculated. The calculation method is: mmol.h / L=1 / 2(G 0 +G 30 )*30+1 / 2(G 30 +G 60 )*30+1 / 2(G 60 +G 90 )*30+1 / 2(G 90 +G 120 )*30(G 0 , G 30 , G 60 , G 90 , G 120 The blood glucose values ​​were measured at 0, 30, 60, 90 and 120 min respectively) and the modeling standard was as follows: the fasting blood glucose of the model group was similar to that of the blank group, but the area under the curve was higher than that of the blank group, and there was a statistical difference.

[0042] Administration: After the impaired glucose tolerance rats were successfully modeled, they were divided into 7 groups. The blank group and the model group were given equal amounts of normal saline by gavage, and the oligofructose was 95% oligofructose syrup. The dosage of each group is shown in Table 2 (Ajutian group 1: L-arabinose + inulin + betaine, (2+2+2) mg / kg; Ajutian group 2: L-arabinose + inulin + betaine, (20+20+10) mg / kg; combination group 1: oligofructose + L-arabinose + inulin + betaine, (2000+2+2+2) mg / kg; combination group 2: oligofructose + L-arabinose + inulin + betaine, (2500+20+20+10) mg / kg. Except for the blank group, the other groups were fed with high-fat feed for 20 days except for the corresponding ingredients by gavage, and then a glucose tolerance test was performed to compare the blood glucose value AUC of each group and the changes in blood glucose value in each time period.

[0043] Statistical methods: The experimental data are The t test was used for comparison between the groups. P < 0.05 indicated a significant statistical difference, and P < 0.01 indicated a very significant statistical difference.

[0044] Table 2: Effects of the composition on blood glucose levels in rats with impaired glucose tolerance ( n=9~10)

[0045]

[0046] Note: Compared with the model group, # P<0.05, ## P<0.01; compared with the same dosage of oligofructose group, * P<0.05, ** P<0.01.

[0047] As shown in the experimental results in Table 2, the fasting blood glucose value of the model group was similar to that of the blank group rats; the postprandial blood glucose and AUC of the model group were significantly higher than those of the blank group, and had very significant statistical differences compared with the blank group.

[0048] The postprandial blood glucose values ​​and AUC values ​​of oligofructose group 1 and group 2 were similar, and there was no significant statistical difference between the two groups. The blood glucose values ​​of oligofructose group 1 and group 2 at 30 minutes after meal were significantly lower than those of the model group, with significant statistical differences; the blood glucose values ​​of oligofructose group 1 and group 2 at 60 minutes, 90 minutes and 120 minutes after meal were slightly lower than those of the model group, but did not show significance. This shows that oligofructose has a significant hypoglycemic effect 30 minutes after meal, but over time, the above effect of oligofructose decreases significantly.

[0049] The blood glucose and AUC values ​​of the ajutian group 1 and group 2 were similar, and there was no significant statistical difference compared with the model group, indicating that the ajutian composition in this dosage range had no significant effect on blood glucose.

[0050] Compared with the model group, the blood glucose levels and AUC values ​​of composition group 1 and group 2 at 30min, 60min, and 90min after meal were significantly decreased, with significant statistical differences. Compared with the oligofructose group at the same dose, composition group 1 and composition group 2 significantly reduced the blood glucose levels at 60min and 90min after meal, but had no significant effect on the blood glucose level at 30min after meal. The above results show that the combination of the Ajutian composition and oligofructose can prolong the hypoglycemic effect time of oligofructose, thereby further promoting the hypoglycemic effect of oligofructose.

Claims

1. A prebiotic composition beneficial to health, comprising: (1) 50-98% by weight of oligofructose; (2) 0.2-0.7% by weight of L-arabinose; (3) 0.2-0.7% by weight of inulin; (4) 0.2-0.7% by weight of betaine; (5) Appropriate amount of water.

2. The prebiotic composition according to claim 1, characterized in that The oligofructose is oligofructose powder or oligofructose syrup.

3. The prebiotic composition according to claim 2, characterized in that The concentration of the oligofructose syrup is 40%-95%, preferably the concentration of the oligofructose syrup is 55-95%.

4. The prebiotic composition according to claim 3, characterized in that The dosage of the oligofructose syrup is in the range of 10-50 g, the dosage of L-arabinose is in the range of 0.01-0.5 g, the dosage of inulin is in the range of 0.01-0.5 g, and the dosage of betaine is in the range of 0.01-0.5 g.

5. The prebiotic composition according to claim 4, characterized in that The dosage of the oligofructose syrup is in the range of 20-25 g, the dosage of L-arabinose is in the range of 0.1-0.2 g, the dosage of inulin is in the range of 0.1-0.2 g, the dosage of betaine is in the range of 0.05-0.15 g, and the dosage of water is in the range of 0.2-1 g.

6. The prebiotic composition according to claim 5, characterized in that The dosage of the oligofructose syrup is in the range of 20-20.5 g, the dosage of L-arabinose is in the range of 0.1-0.15 g, the dosage of inulin is in the range of 0.1-0.15 g, the dosage of betaine is in the range of 0.1-0.15 g, and the dosage of water is in the range of 0.2-0.5 g.

7. The prebiotic composition according to claim 1, characterized in that The prebiotic composition can be made into tablets, granules, capsules, oral liquids, or added into food or beverages.

8. Use of the prebiotic composition according to claim 1 in preparing a product for relieving constipation.

9. Use of the prebiotic composition according to claim 1 in preparing a product for regulating blood sugar.

Images